Sarah S Bernards1, Barbara M Norquist2, Maria I Harrell3, Kathy J Agnew4, Ming K Lee5, Tom Walsh6, Elizabeth M Swisher7. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: sarahb18@uw.edu. 2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: bnorquis@uw.edu. 3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: maribel@uw.edu. 4. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: kagnew@uw.edu. 5. Division of Medical Genetics, Department of Medicine, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: mlee@uw.edu. 6. Division of Medical Genetics, Department of Medicine, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: twalsh@uw.edu. 7. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA; Division of Medical Genetics, Department of Medicine, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: swishere@uw.edu.
Abstract
OBJECTIVE: Ovarian carcinoma (OC) is rare in young women and the fraction of early onset OC attributable to inherited mutations in known OC genes is uncertain. We sought to characterize the fraction of OC that is heritable in women diagnosed with ovarian, fallopian tube, or peritoneal carcinoma at forty years of age or younger. METHODS: We sequenced germline DNA from forty-seven women diagnosed with OC at age 40 or younger ascertained through a gynecologic oncology tissue bank or referred from outside providers using BROCA, a targeted capture and massively parallel sequencing platform that can detect all mutation classes. We evaluated 11 genes associated with ovarian carcinoma (BARD1, BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51D, and RAD51C) and additional candidate genes in DNA repair (ATM, BAP1, CHEK2, MRE11A, NBN, PTEN, TP53). We counted only clearly damaging mutations. RESULTS: Damaging mutations in OC genes were identified in 13 of 47 (28%) subjects, of which 10 (77%) occurred in BRCA1 and one each occurred in BRCA2, MSH2, and RAD51D. Women with a strong family history were no more likely to have an OC gene mutation (8/17, 47%) than those without a strong family history (9/30, 30%, P=0.35). Additionally, damaging mutations in non-OC genes were identified, one in NBN and one in CHEK2. CONCLUSIONS: A high proportion of young women with invasive OC have mutations in BRCA1, and a smaller fraction have mutations in other known OC genes. Family history was not associated with mutation status in these early onset cases.
OBJECTIVE:Ovarian carcinoma (OC) is rare in young women and the fraction of early onset OC attributable to inherited mutations in known OC genes is uncertain. We sought to characterize the fraction of OC that is heritable in women diagnosed with ovarian, fallopian tube, or peritoneal carcinoma at forty years of age or younger. METHODS: We sequenced germline DNA from forty-seven women diagnosed with OC at age 40 or younger ascertained through a gynecologic oncology tissue bank or referred from outside providers using BROCA, a targeted capture and massively parallel sequencing platform that can detect all mutation classes. We evaluated 11 genes associated with ovarian carcinoma (BARD1, BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51D, and RAD51C) and additional candidate genes in DNA repair (ATM, BAP1, CHEK2, MRE11A, NBN, PTEN, TP53). We counted only clearly damaging mutations. RESULTS: Damaging mutations in OC genes were identified in 13 of 47 (28%) subjects, of which 10 (77%) occurred in BRCA1 and one each occurred in BRCA2, MSH2, and RAD51D. Women with a strong family history were no more likely to have an OC gene mutation (8/17, 47%) than those without a strong family history (9/30, 30%, P=0.35). Additionally, damaging mutations in non-OC genes were identified, one in NBN and one in CHEK2. CONCLUSIONS: A high proportion of young women with invasive OC have mutations in BRCA1, and a smaller fraction have mutations in other known OC genes. Family history was not associated with mutation status in these early onset cases.
Authors: F Coulet; A Fajac; C Colas; M Eyries; A Dion-Minière; R Rouzier; S Uzan; J-P Lefranc; M Carbonnel; F Cornelis; A Cortez; F Soubrier Journal: Clin Genet Date: 2012-07-23 Impact factor: 4.438
Authors: Tom Walsh; Silvia Casadei; Ming K Lee; Christopher C Pennil; Alex S Nord; Anne M Thornton; Wendy Roeb; Kathy J Agnew; Sunday M Stray; Anneka Wickramanayake; Barbara Norquist; Kathryn P Pennington; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher Journal: Proc Natl Acad Sci U S A Date: 2011-10-17 Impact factor: 11.205
Authors: Amy P M Finch; Jan Lubinski; Pål Møller; Christian F Singer; Beth Karlan; Leigha Senter; Barry Rosen; Lovise Maehle; Parviz Ghadirian; Cezary Cybulski; Tomasz Huzarski; Andrea Eisen; William D Foulkes; Charmaine Kim-Sing; Peter Ainsworth; Nadine Tung; Henry T Lynch; Susan Neuhausen; Kelly A Metcalfe; Islay Thompson; Joan Murphy; Ping Sun; Steven A Narod Journal: J Clin Oncol Date: 2014-02-24 Impact factor: 44.544
Authors: Thorunn Rafnar; Daniel F Gudbjartsson; Patrick Sulem; Aslaug Jonasdottir; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Soren Besenbacher; Pär Lundin; Simon N Stacey; Julius Gudmundsson; Olafur T Magnusson; Louise le Roux; Gudbjorg Orlygsdottir; Hafdis T Helgadottir; Hrefna Johannsdottir; Arnaldur Gylfason; Laufey Tryggvadottir; Jon G Jonasson; Ana de Juan; Eugenia Ortega; Jose M Ramon-Cajal; Maria D García-Prats; Carlos Mayordomo; Angeles Panadero; Fernando Rivera; Katja K H Aben; Anne M van Altena; Leon F A G Massuger; Mervi Aavikko; Paula M Kujala; Synnöve Staff; Lauri A Aaltonen; Kristrun Olafsdottir; Johannes Bjornsson; Augustine Kong; Anna Salvarsdottir; Hafsteinn Saemundsson; Karl Olafsson; Kristrun R Benediktsdottir; Jeffrey Gulcher; Gisli Masson; Lambertus A Kiemeney; Jose I Mayordomo; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nat Genet Date: 2011-10-02 Impact factor: 38.330
Authors: Brian Shuch; Srinivas Vourganti; Christopher J Ricketts; Lindsay Middleton; James Peterson; Maria J Merino; Adam R Metwalli; Ramaprasad Srinivasan; W Marston Linehan Journal: J Clin Oncol Date: 2013-12-30 Impact factor: 44.544
Authors: Marieke Arts-de Jong; Catharina M Manders; Nicoline Hoogerbrugge; Marjolijn J L Ligtenberg; Leon F Massuger; Joanne A de Hullu; Liesbeth Spruijt Journal: Int J Gynecol Cancer Date: 2013-10 Impact factor: 3.437
Authors: T Pal; M R Akbari; P Sun; J-H Lee; J Fulp; Z Thompson; D Coppola; S Nicosia; T A Sellers; J McLaughlin; H A Risch; B Rosen; P Shaw; J Schildkraut; S A Narod Journal: Br J Cancer Date: 2012-10-09 Impact factor: 7.640
Authors: Sidrah Shah; Alison Cheung; Mikolaj Kutka; Matin Sheriff; Stergios Boussios Journal: Int J Environ Res Public Health Date: 2022-07-01 Impact factor: 4.614
Authors: Wejdan M Alenezi; Larissa Milano; Caitlin T Fierheller; Corinne Serruya; Timothée Revil; Kathleen K Oros; Supriya Behl; Suzanna L Arcand; Porangana Nayar; Dan Spiegelman; Simon Gravel; Anne-Marie Mes-Masson; Diane Provencher; William D Foulkes; Zaki El Haffaf; Guy Rouleau; Luigi Bouchard; Celia M T Greenwood; Jean-Yves Masson; Jiannis Ragoussis; Patricia N Tonin Journal: Cancers (Basel) Date: 2022-04-30 Impact factor: 6.575
Authors: Miriam Deniz; Tatiana Romashova; Sarah Kostezka; Anke Faul; Theresa Gundelach; Maria Moreno-Villanueva; Wolfgang Janni; Thomas W P Friedl; Lisa Wiesmüller Journal: Oncotarget Date: 2017-10-09
Authors: Dominique Schell; Shahid Ullah; Mark E Brooke-Smith; Paul Hollington; Marina Yeow; Christos S Karapetis; David I Watson; Stephen J Pandol; Claire T Roberts; Savio G Barreto Journal: Cancers (Basel) Date: 2022-01-06 Impact factor: 6.639